EntryPoint Capital LLC Acquires 73,061 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

EntryPoint Capital LLC grew its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 259.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 101,205 shares of the medical instruments supplier’s stock after acquiring an additional 73,061 shares during the period. EntryPoint Capital LLC’s holdings in OraSure Technologies were worth $365,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Peapod Lane Capital LLC bought a new position in OraSure Technologies during the 4th quarter worth $1,730,000. American Century Companies Inc. increased its stake in shares of OraSure Technologies by 11.4% in the fourth quarter. American Century Companies Inc. now owns 2,345,837 shares of the medical instruments supplier’s stock valued at $8,468,000 after buying an additional 240,224 shares during the period. Jacobs Levy Equity Management Inc. raised its position in shares of OraSure Technologies by 66.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 524,950 shares of the medical instruments supplier’s stock worth $2,242,000 after acquiring an additional 209,580 shares during the last quarter. Walleye Capital LLC acquired a new position in shares of OraSure Technologies in the third quarter worth approximately $835,000. Finally, KLP Kapitalforvaltning AS bought a new stake in OraSure Technologies in the fourth quarter valued at approximately $664,000. Institutional investors and hedge funds own 93.50% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th.

OraSure Technologies Trading Down 2.9 %

Shares of OraSure Technologies stock opened at $3.39 on Thursday. The business has a 50-day moving average price of $3.70 and a two-hundred day moving average price of $3.89. OraSure Technologies, Inc. has a 1-year low of $2.69 and a 1-year high of $6.35. The company has a market cap of $253.57 million, a P/E ratio of 22.60 and a beta of -0.02.

OraSure Technologies declared that its board has authorized a share repurchase program on Monday, March 24th that permits the company to buyback $40.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to repurchase up to 15.6% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its shares are undervalued.

Insider Activity at OraSure Technologies

In related news, Director John P. Kenny acquired 47,659 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were purchased at an average price of $3.17 per share, for a total transaction of $151,079.03. Following the completion of the acquisition, the director now owns 70,915 shares of the company’s stock, valued at approximately $224,800.55. This trade represents a 204.93 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Manner Carrie Eglinton acquired 78,625 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were bought at an average cost of $3.15 per share, for a total transaction of $247,668.75. Following the transaction, the chief executive officer now directly owns 1,259,664 shares in the company, valued at approximately $3,967,941.60. This represents a 6.66 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 190,284 shares of company stock worth $600,348 in the last 90 days. Corporate insiders own 3.40% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.